Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + S-1 with radiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2100053982Phase 4Recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and tegafur in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: objective response rate and progression-free survival. Started Dec 2021; status: recruiting.
02
Drugs
fluzoparibtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100053982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053982.